Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: Health Care Reform: A Comparison Of The Senate And House Bills

You may also be interested in...



Brand Drug Repackaging Helps Drive Extraordinary Price Increases - GAO

Repackaged versions of many of the most widely prescribed brand-name drugs appear on a list of those with "extraordinary" price increases between 2000 and 2008, data from a recent analysis by the Government Accountability Office show

As Health Reform Takes Final Shape, Pharma Provisions Still In Play

Even as news that a breakthrough on one of the major issues separating the House and Senate health care reform bills - taxing high-cost health care plans -emerged near the end of the week of Jan. 11, issues of keen interest for biopharma stakeholders remained unsettled

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS051812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel